Yoav Charpak-Amikam

Yoav Charpak-Amikam

Auto-generated profile, based on publicly available information

Yoav Charpak-Amikam

The Concern Foundation Laboratories at the Lautenberg Center for Immunology and Cancer Research, Hebrew University Medical School, IMRIC, Jerusalem, Israel

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TGTamara Goldfarb
Tamara Goldfarb
HSHila Sberro
Hila Sberro
EWEyal Weinstock
Eyal Weinstock
OCOfir Cohen
Ofir Cohen
SDShany Doron
Shany Doron
RSRotem Sorek
Rotem Sorek
The perpetual arms race between bacteria and phage has resulted in the evolution of efficient resistance systems that protect bacteria from phage infection. Such systems, which include the CRISPR‐Cas and restriction‐modification systems, have proven to be invaluable in the biotechnology and dairy industries. Here, we report on a six‐gene cassette in Bacillus cereus which, when integrated into the Bacillus subtilis genome, confers resistance to a broad range of phages, including both virulent and temperate ones. This cassette includes a putative Lon‐like protease, an alkaline phosphatase domain protein, a putative RNA‐binding protein, a DNA methylase, an ATPase‐domain protein, and a protein of unknown function. We denote this novel defense system BREX (Bacteriophage Exclusion) and show that it allows phage adsorption but blocks phage DNA replication. Furthermore, our results suggest that methylation on non‐palindromic TAGGAG motifs in the bacterial genome guides self/non‐self discrimination and is essential for the defensive function of the BREX system. However, unlike restriction‐modification systems, phage DNA does not appear to be cleaved or degraded by BREX, suggesting a novel mechanism of defense. Pan genomic analysis revealed that BREX and BREX‐like systems, including the distantly related Pgl system described in Streptomyces coelicolor , are widely distributed in ~10% of all sequenced microbial genomes and can be divided into six coherent subtypes in which the gene composition and order is conserved. Finally, we detected a phage family that evades the BREX defense, implying that anti‐BREX mechanisms may have evolved in some phages as part of their arms race with bacteria. ![][1] BREX is a novel host DNA methylation‐based defense system that protects B. cereus against a broad variety of phages. BREX‐like systems can be found in 10% of sequenced bacterial genomes. [1]: pending:yes

20 December 2013 in eLife
Verified
Journal Article
Open access
AYAvihu H Yona
Avihu H Yona
ZBZohar Bloom-Ackermann
Zohar Bloom-Ackermann
IFIdan Frumkin
Idan Frumkin
VHVictor Hanson-Smith
Victor Hanson-Smith
YCYoav Charpak-Amikam
Yoav Charpak-Amikam
YPYitzhak Pilpel
Yitzhak Pilpel
Changes in expression patterns may occur when organisms are presented with new environmental challenges, for example following migration or genetic changes. To elucidate the mechanisms by which the translational machinery adapts to such changes, we perturbed the tRNA pool of Saccharomyces cerevisiae by tRNA gene deletion. We then evolved the deletion strain and observed that the genetic adaptation was recurrently based on a strategic mutation that changed the anticodon of other tRNA genes to match that of the deleted one. Strikingly, a systematic search in hundreds of genomes revealed that anticodon mutations occur throughout the tree of life. We further show that the evolution of the tRNA pool also depends on the need to properly couple translation to protein folding. Together, our observations shed light on the evolution of the tRNA pool, demonstrating that mutation in the anticodons of tRNA genes is a common adaptive mechanism when meeting new translational demands.

4 June 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ARAdi Reches
Adi Reches
YOYael Ophir
Yael Ophir
NSNatan Stein
Natan Stein
IKInbal Kol
Inbal Kol
BIBatya Isaacson
Batya Isaacson
OMOfer Mandelboim
Ofer Mandelboim
Background The use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity. Methods We stained human natural killer cells using fusion proteins composed of the extracellular portion of various tumor markers fused to the Fc portion of human IgG1, and identified Nectin4 as a novel TIGIT ligand. Next, we generated a novel Nectin4 blocking antibody and demonstrated its efficacy as a checkpoint inhibitor in killing assays and in vivo. Results We identify Nectin4 to be a novel ligand of TIGIT. We showed that, as opposed to all other known TIGIT ligands, which bind also additional receptors, Nectin4 interacts only with TIGIT. We show that the TIGIT-Nectin4 interaction inhibits natural killer cell activity, a critical part of the innate immune response. Finally, we developed blocking Nectin4 antibodies and demonstrated that they enhance tumor killing in vitro and in vivo. Conclusion We discovered that Nectin4 is a novel ligand for TIGIT and demonstrated that specific antibodies against it enhance tumor cell killing in vitro and in vivo. Since Nectin4 is expressed almost exclusively on tumor cells, our Nectin4-blocking antibodies represent a combination of cancer specificity and immune checkpoint activity, which may prove more effective and safe for cancer immunotherapy.

1 October 2016 in Cell Host & Microbe
Verified
Journal Article
Closed access
AVAlon Vitenshtein
Alon Vitenshtein
YCYoav Charpak-Amikam
Yoav Charpak-Amikam
RYRachel Yamin
Rachel Yamin
YBYoav Bauman
Yoav Bauman
BIBatya Isaacson
Batya Isaacson
OMOfer Mandelboim
Ofer Mandelboim

1 January 2019 in iScience
Verified
Journal Article
Open access
NSNatan Stein
Natan Stein
OBOrit Berhani
Orit Berhani
DSDominik Schmiedel
Dominik Schmiedel
ADAlexandra Duev-Cohen
Alexandra Duev-Cohen
ESEinat Seidel
Einat Seidel
OMOfer Mandelboim
Ofer Mandelboim
Long, non-coding RNAs (lncRNAs) are involved in the regulation of many cellular processes. The lncRNA IFNG-AS1 was found to strongly influence the responses to several pathogens in mice by increasing interferon gamma (IFNγ) secretion. Studies have looked at IFNG-AS1 in T cells, yet IFNG-AS1 function in natural killer cells (NKs), an important source of IFNγ, remains unknown. Here, we show a previously undescribed sequence of IFNG-AS1 and report that it may be more abundant in cells than previously thought. Using primary human NKs and an NK line with IFNG-AS1 overexpression, we show that IFNG-AS1 is quickly induced upon NK cell activation, and that IFNG-AS1 overexpression leads to increased IFNγ secretion. Taken together, our work expands IFNG-AS1's activity to the innate arm of the type I immune response, helping to explain its notable effect in animal models of disease.

17 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YCYoav Charpak-Amikam
Yoav Charpak-Amikam
TKTobias Kubsch
Tobias Kubsch
ESEinat Seidel
Einat Seidel
EOEsther Oiknine-Djian
Esther Oiknine-Djian
NCNoemi Cavaletto
Noemi Cavaletto
OMOfer Mandelboim
Ofer Mandelboim
Human cytomegalovirus (HCMV) is a major human pathogen, causing serious diseases in immunocompromised populations and congenially infected neonates. One of the main immune cells acting against the virus are Natural Killer (NK) cells. Killing by NK cells is mediated by a small family of activating receptors such as NKp30 that interact with the cellular ligand B7-H6. The outcome of B7-H6-NKp30 interaction was, so far, mainly studied with regard to NK recognition and killing of tumors. Here, we demonstrated that the expression of B7-H6 is upregulated following HCMV infection and that HCMV uses two of its genes: US18 and US20, to interfere with B7-H6 surface expression, in a mechanism involving endosomal degradation, in order to evade NK cell recognition.